Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Receivables (2021 - 2025)

Indivior Pharmaceuticals has reported Receivables over the past 5 years, most recently at $255.0 million for Q4 2025.

  • Quarterly results put Receivables at $255.0 million for Q4 2025, changed 0.39% from a year ago — trailing twelve months through Dec 2025 was $255.0 million (changed 0.39% YoY), and the annual figure for FY2025 was $255.0 million, changed 0.39%.
  • Receivables for Q4 2025 was $255.0 million at Indivior Pharmaceuticals, down from $259.0 million in the prior quarter.
  • Over the last five years, Receivables for INDV hit a ceiling of $259.0 million in Q3 2025 and a floor of $202.0 million in Q4 2021.
  • Median Receivables over the past 5 years was $249.0 million (2023), compared with a mean of $241.2 million.
  • Biggest five-year swings in Receivables: grew 15.91% in 2023 and later dropped 0.39% in 2025.
  • Indivior Pharmaceuticals' Receivables stood at $202.0 million in 2021, then rose by 8.91% to $220.0 million in 2022, then rose by 15.91% to $255.0 million in 2023, then rose by 0.39% to $256.0 million in 2024, then dropped by 0.39% to $255.0 million in 2025.
  • The last three reported values for Receivables were $255.0 million (Q4 2025), $259.0 million (Q3 2025), and $240.0 million (Q2 2025) per Business Quant data.